Given the scarcity of truly tumor-specific antigens (absent on normal cells) and substantial tumor heterogeneity, pan-T-cell antigens (such as CD5 and CD7) have emerged as the predominant targets in clinical trials for T-cell malignancies [92]. Here, CD7 is linked to neoplasm.